natgillin/translations-raw huggingface dataset:
Nøje overvågning af terapeutiske virkninger og bivirkninger anbefales, når loratidin indgives sammen med ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when loratidine is concomitantly administered with ritonavir.
Midler mod infektion Fusidinsyre
Anti-infectives Fusidic Acid
Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjet plasmakoncentration af både fusidinsyre og af ritonavir og er derfor kontraindiceret (se pkt 4. 3).
Ritonavir co-administration is likely to result in increased plasma concentrations of both fusidic acid and ritonavir and is therefore contraindicated (see section 4.3).
150 daglig 500 hver 12. ↑ 4 gange ↑ 2, 5 gange time ↑ 16 gange
150 daily 500 q12h, ↑ 4-fold ↑ 2.5-fold
14 Ritonavirs virkning på ikke- antiretrovirale samtidigt indgivne lægemidler Samtidigt indgivet lægemiddel 25- O- desacetyl rifabutin metabolit
14 Ritonavir effects on Non-antiretroviral Co-administered Drugs Co-administered Drug
Virkning på samtidigt indgivet lægemiddel, AUC ↑ 38 gange
Effect on Co- administered Drug AUC
4. 3).
Due to the large increase in rifabutin AUC, the concomitant use of rifabutin with ritonavir dosed as an antiretroviral agent is contraindicated (see section 4.3).
Den officielle vejledning vedrørende den hensigtsmæssige behandling af tuberkulose hos HIV- inficerede patienter bør tages i betragtning.
Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV-infected patients.
Selvom rifampicin kan inducerer ritonavirs metabolisme, tyder begrænsede data på, at rifampicins øgede inducerende effekt (ved siden af ritonavirs egen) er lille og ikke har nogen klinisk relevant effekt på ritonavir- niveauer i højdosis enkeltstof- behandling.
Although rifampicin may induce metabolism of ritonavir, limited data indicate that when high doses of ritonavir (600 mg twice daily) is co-administered with rifampicin, the additional inducing effect of rifampicin (next to that of ritonavir itself) is small and may have no clinical relevant effect on ritonavir levels in high-dose ritonavir therapy.
4. 3).
200 q12h 400 q12h ↓ 82% ↓ 66% 200 q12h 100 q12h ↓ 39% ↓ 24% Concomitant use of ritonavir dosed as an antiretroviral agent and voriconazole is contraindicated due to reduction in voriconazole concentrations (see section 4.3).
Samtidig anvendelse af voriconazol og ritonavir doseret som en farmakokinetisk forstærker bør undgås, medmindre en vurdering af benefit/ risk- forholdet for patienten berettiger brugen af voriconazol.
Co-administration of voriconazole and ritonavir dosed as a pharmacokinetic enhancer should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
Clarithromycin
Clarithromycin
200 hver 8. ↑ 77% ↑ 31% time, time
500 q12h, 200 q8h ↑ 77% ↑ 31%
14- OH clarithromycin metabolit
14-OH clarithromycin metabolite
↓ 100% ↓ 99% På grund af clarithromycins store terapeutiske område bør det ikke være nødvendigt at foretage nogen nedsættelse af dosis for patienter med normal nyrefunktion.
Due to the large therapeutic window of clarithromycin no dose reduction should be necessary in patients with normal renal function.
For patienter med nedsat nyrefunktion bør en dosisnedsættelse overvejes: til patienter med en kreatininclearance på 30 til 60 ml/ min. bør dosis reduceres med 50%, til patienter med en kreatininclearance under 30 ml/ min. bør dosis reduceres med 75%.
For patients with renal impairment, a clarithromycin dose reduction should be considered: for patients with creatinine clearance of 30 to 60 ml/min the dose should be reduced by 50%, for patients with creatinine clearance less than 30 ml/min the dose should be reduced by 75%.
200 daglig 500 hver 12. ↑ 3, 4 gange ↑ 55%
200 daily 500 q12h ↑ 3.4-fold ↑ 55%
15 Ritonavirs virkning på ikke- antiretrovirale samtidigt indgivne lægemidler Samtidigt indgivet lægemiddel
15 Ritonavir effects on Non-antiretroviral Co-administered Drugs Co-administered Drug
Dosis af Norvir (mg) time
Dose of NORVIR (mg)
Ritonavir hæmmer den CYP3A- medierede metabolisme af ketoconazol.
Ritonavir inhibits CYP3A-mediated metabolism of ketoconazole.
På grund af en øget forekomst af gastrointestinale og hepatiske bivirkninger bør det overvejes at reducere dosis af ketoconazol, når det indgives sammen med ritonavir doseret som et antiretroviralt stof eller som en farmakokinetisk forstærker.
Due to an increased incidence of gastrointestinal and hepatic adverse events, a dose reduction of ketoconazole should be considered when co- administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Sulfamethoxazol/ Trimethoprim2
Sulfamethoxazole/Trimethoprim2
800/ 160, enkelt dosis
800/160, single dose
500 hver 12. ↓ 20% / ↑ 20% time
500 q12h
Dosisændring af sulfamethoxazol/ trimethoprim under samtidig behandling med ritonavir skulle ikke være nødvendig.
Dose alteration of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should not be necessary.
Antipsykotika/ Neuroleptika Clozapin, pimozid
Antipsychotics/Neuroleptics Clozapine, pimozide
Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjede plasmakoncentrationer af clozapin eller pimozid og er derfor kontraindiceret (se pkt 4. 3).
Ritonavir co-administration is likely to result in increased plasma concentrations of clozapine or pimozide and is therefore contraindicated (see section 4.3).
Nøje overvågning af terapeutiske virkninger og bivirkninger anbefales, når disse lægemidler indgives sammen med ritonavir i antiretrovirale doser (se pkt 4. 3).
Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir (see section 4.3).
Calciumantagonister Amlodipin, diltiazem, nifedipin
Calcium channel antagonists Amlodipine, diltiazem, nifedipine
Ergotamin Derivater
Ergot Derivatives
Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjet plasmakoncentration af ergotaminderivater og er derfor kontraindiceret (se pkt 4. 3).
Ritonavir co-administration is likely to result in increased plasma concentrations of ergot derivatives and is therefore contraindicated (see section 4.3).
Peristaltikfremmende midler Cisaprid
GI motility agent Cisapride
Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjet plasmakoncentration af cisaprid og er derfor kontraindiceret (se pkt 4. 3).
Ritonavir co-administration is likely to result in increased plasma concentrations of cisapride and is therefore contraindicated (see section 4.3).
16 Ritonavirs virkning på ikke- antiretrovirale samtidigt indgivne lægemidler Samtidigt indgivet lægemiddel
16 Ritonavir effects on Non-antiretroviral Co-administered Drugs Co-administered Drug
HMG Co- A Reduktasehæmmere
HMG Co-A Reductase Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, Pravstatin, Rosuvastatin, Simvastatin
Atorvastatin, Fluvastatin, Lovastatin, Pravstatin, Rosuvastatin, Simvastatin
HMG- CoA reduktasehæmmere, som i høj grad er afhængige af CYP3A- metabolisme, f. eks. lovastatin og simvastatin, forventes at få markant øgede plasmakoncentrationer ved samtidig indgift af ritonavir doseret som et antiretroviralt stof eller som en farmakokinetisk forstærker.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
4. 3).
Since increased concentrations of lovastatin and simvastatin may predispose patients to myopathies, including rhabdomyolysis, the combination of these medicinal products with ritonavir is contraindicated (see section 4.3).
Hvis behandling med en HMG- CoA reductasehæmmer er indiceret, anbefales pravastatin eller fluvastatin.
If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Hormonale kontraceptiva
Hormonal contraceptive Ethinyl estradiol
Ethinylestradiol
50 µg single dose
50 µg, enkeltdosis 500 hver 12. ↓ 40% ↓ 32% time På grund af nedsættelse af ethinylestradiolkoncentrationerne bør barrieremetoder eller andre ikke- hormonelle antikonceptionsmidler overvejes ved samtidig anvendelse af ritonavir doseret som et antiretroviralt stof eller som en farmakokinetisk forstærker.
Due to reductions in ethinyl estradiol concentrations, barrier or other non-hormonal methods of contraception should be considered with concomitant ritonavir use when dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
4. 4).
Ritonavir is likely to change the uterine bleeding profile and reduce the effectiveness of estradiol-containing contraceptives (see section 4.4).
Immunosupressiva Cyclosporin, tacrolimus, everolimus
Immunosupressants Cyclosporine, tacrolimus, everolimus
Ritonavir doseret som en farmakokinetisk forstærker eller som et antiretroviralt stof hæmmer CYP3A4 og forventes som følge heraf at øge plasmakoncentrationerne af cyclosporin, tacrolimus eller everolimus.
Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of cyclosporine, tacrolimus or everolimus.
Phosphodiesterasehæmmere Sildenafil
Phosphodiesterase inhibitors Sildenafil
100, enkeltdosis
100, single dose
↑ 11 gange
↑ 11-fold
4. 4).
Concomitant use of sildenafil with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer is not recommended and in no instance should sildenafil doses exceed 25 mg in 48 hours (see also section 4.4).
Samtidig brug af sildenafil og ritonavir er kontraindiceret til patienter med pulmonal arteriel hypertension.
Concomitant use of sildenafil with ritonavir is contraindicated in pulmonary arterial hypertension patients.
20, enkeltdosis
20, single dose
Virkning på samtidigt indgivet lægemiddel, AUC
200 q12h
Virkning på samtidigt indgivet lægemiddel, Cmax
↔
4. 4).
The concomitant use of tadalafil with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer should be with caution at reduced doses of no more than 10 mg tadalafil every 72 hours with increased monitoring for adverse events (see section 4.4).
Vardenafil
Vardenafil
5, enkeltdosis
5, single
↑ 13 gange
↑ 13-fold
4. 4).
The concomitant use of vardenafil and ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer should be with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring for adverse events (see section 4.4).
Sedativa/ hypnoptika Clorazepat, diazepam, estazolam, flurazepam, oral og parenteral midazolam og triazolam
Sedatives/hynoptics Clorazepate, diazepam, estazolam, flurazepam, oral and parenteral midazolam and triazolam
Samtidig administration af Ritonavir vil sandsynligvis resultere i forhøjede plasmakoncentrationer af clorazepat, diazepam, estazolam, flurazepam og midazolam og er derfor kontraindiceret (se pkt 4. 3).
Ritonavir co-administration is likely to result in increased plasma concentrations of clorazepate, diazepam, estazolam and flurazepam and is therefore contraindicated (see section 4.3).
Der er ikke udført interaktionsforsøg med samtidig administration af Norvir med benzodiazepiner.
No drug interaction study has been performed for the co-administration of Norvir with benzodiazepines.
Baseret på data fra andre CYP3A4- hæmmere forventes plasmakoncentrationerne af midazolam at være signifikant højere, når midazolam gives oralt.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.
Norvir bør derfor ikke administreres samtidig med oralt administreret midazolam (se pkt 4. 3), hvorimod der bør udvises forsigtighed ved samtidig administration af Norvir og parenteral midazolam.
Therefore, Norvir should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of Norvir and parenteral midazolam.
Data fra samtidig anvendelse af parenteral midazolam med andre protease- hæmmere tyder på en mulig stigning på 3 – 4 gange i plasmaniveauerne for midazolam.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3 – 4 fold increase in midazolam plasma levels.
Hvis Norvir administreres samtidig med parenteral midazolam, bør det gøres på en intensivafdeling (ICU) eller under lignende forhold, der sikrer tæt klinisk monitorering og passende medicinsk behandling i tilfælde af respirationsdepression og/ eller forlænget sedation.
If Norvir is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
0, 125, enkeltdosis 200, 4 doser ↑ > 20 gange ↑ 87% Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjede plasmakoncentrationer af triazolam og er derfor kontraindiceret (se pkt 4. 3).
0.125 single dose 200, 4 doses ↑ > 20 fold ↑ 87% Ritonavir co-administration is likely to result in increased plasma concentrations of triazolam and is therefore contraindicated (see section 4.3).
Meperidin
Meperidine
50 enkeltdosis 500 hver 12. ↓ 62% ↓ 59% oral time
50 oral single dose
Normeperidine metabolit
Normeperidine metabolite
↑ 47% ↑ 87% Anvendelsen af meperidin sammen med ritonavir er kontraindiceret på grund af de øgede koncentrationer af metabolitten, normeperidin, som både har smertestillende og centralstimulende virkning.
The use of meperidine and ritonavir is contraindicated due to the increased concentrations of the metabolite, normeperidine, which has both analgesic and CNS stimulant activity.
4. 3.
Elevated normeperidine concentrations may increase the risk of CNS effects (eg, seizures), see section 4.3.
500 hver 12. time, 2 dage
200 q12h, 2 days
↑2. 5 gange
↑2.5 fold
500 hver 12. time, 10 dage
500 q12h, 10 days
↓ 12%
↓ 12%
18 Ritonavirs virkning på ikke- antiretrovirale samtidigt indgivne lægemidler Samtidigt indgivet lægemiddel
18 Ritonavir effects on Non-antiretroviral Co-administered Drugs Co-administered Drug
Buspirone
Buspirone
Sovemidler Zolpidem
Sleeping agent Zolpidem
200, 4 doser
200, 4 doses
↑ 22%
↑ 22%
Rygeophør Bupropion
Smoke cessation Bupropion
100 mg hver 12. time
100 mg q12h 600 mg q12h
↓ 22%
↓ 22% ↓ 66%
↓ 21%
↓ 21% ↓ 62%
150 mg
200 µg qd
600 mg hver 12. time
100 q12h
↓ 66%
↑ ~350-fold
↓ 62%
↑ ~ 25-fold
Samtidig administration af bupropion med gentagne doser af ritonavir forventes at formindske bupropion- niveauer.
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression (plasma cortisol levels were noted to be decreased 86% in the above study) have been reported in patients receiving ritonavir and inhaled or intranasal fluticasone propionate; similar effects could also occur with other corticosteroids metabolised by CYP3A eg, budesonide.
Den anbefalede dosis af bupropion skal imidlertid ikke overskrides, fordi ritonavir også er vist at hæmme CYP2B6 in vitro.
Consequently, concomitant administration of ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
I modsætning til lang tids administration af ritonavir, var der ingen signifikant interaktion med bupropion efter kort tids administration af lave doser af ritonavir (200 mg to gange daglig i 2 dage), hvilket tyder på reduktion af bupropion koncentrationer kan begynde adskillige dage efter initiering af samtidig administration af ritonavir.
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (eg, beclomethasone).
Steroider Vandig næsespray med fluticasonpropionat
Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may be required over a longer period.
200, µg q. d.
Dexamethasone
100 hver 12. time
Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with ritonavir.
↑ ~350 gange
Prednisolone
↑ ~ 25 gange
20 200 q12h ↑ 28% ↑ 9%
19 Ritonavirs virkning på ikke- antiretrovirale samtidigt indgivne lægemidler Samtidigt indgivet lægemiddel
19 Ritonavir effects on Non-antiretroviral Co-administered Drugs Co-administered Drug
Ritonavir doseret som en farmakokinetisk forstærker eller som et antiretroviralt stof hæmmer CYP3A og forventes som følge heraf at øge plasmakoncentrationerne af dexamethason.
Careful monitoring of therapeutic and adverse effects is recommended when prednisolone is concomitantly administered with ritonavir.
Nøje overvågning af terapeutiske virkninger og bivirkninger anbefales, når dexamethason indgives sammen med ritonavir.
The AUC of the metabolite prednisolone increased by 37 and 28% after 4 and 14 days ritonavir, respectively.
Baseret på en parallelgruppesammenligning.
Based on a parallel group comparison 2.
Der er rapporteret hjertetilfælde og neurologiske bivirkninger i forbindelse med samtidig indgift af ritonavir og disopyramid, mexiletin eller nefazodon.
Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine or nefazadone.
Muligheden for lægemiddelinteraktion kan ikke udelukkes.
The possibility of drug interaction cannot be excluded.
Ud over de ovenfor anførte interaktioner bør der, da ritonavir i høj grad er proteinbundet, tages højde for en mulig øget terapeutisk virkning og toksisk virkning på grund af ændret proteinbinding af samtidigt indgivne lægemidler.
In addition to the interactions listed above, as ritonavir is highly protein bound, the possibility of increased therapeutic and toxic effects due to protein binding displacement of concomitant medications should be considered.
Vigtige oplysninger vedrørende lægemiddelinteraktioner, når ritonavir anvendes som en farmakokinetisk forstærker, kan også findes i produktresuméet for den samtidigt indgivne proteasehæmmer.
Important information regarding drug interactions when ritonavir is used a pharmacokinetic enhancer is also contained in the Summary of Product Characteristics of the co-administered protease inhibitor.
Protonpumpe- hæmmere og H2- receptor- anatagonister: protonpumpe- hæmmere og H2- receptor - antagonister (f. eks. omeprazol eller ranitidin) kan nedsætte koncentrationen af protease- hæmmere, som administreres samtidig.
Proton pump inhibitors and H2-receptor antagonists: proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce concentrations for co-administered protease inhibitors.
For særlig information vedrørende virkningen af samtidig administration af syrehæmmende midler, se produktresuméet for protease- hæmmeren, som administreres samtidig.
For specific information regarding the impact of co-administration of acid reducing agents, refer to the SmPC of the co-administered protease inhibitor.
Baseret på interaktionsforsøg med ritonavir boostet protease- hæmmere (lopinavir/ ritonavir, atazanavir) ændrer samtidig administration af omeprazol eller ranitidin ikke signifikant ritonavirs effekt som farmakokinetisk forstærker, selv om der er en mindre ændring af eksponering (omkring 6 - 18%).
Based on interaction studies with the ritonavir boosted protease inhibitors (lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of exposure (about 6 - 18%).
Et begrænset antal gravide kvinder (> 800) har været eksponeret for ritonavir under graviditeten; et meget begrænset antal (> 300) har været eksponeret i første trimester.
A limited number (> 800) of pregnant women were exposed to ritonavir during pregnancy; a very limited number (< 300) were exposed during the first trimester.
Disse data refererer overvejende til eksposition, hvor ritonavir blev anvendt i kombinationsbehandling og ikke i terapeutiske ritonavir doser men i lavere doser som farmakokinetisk forstærker for andre PI- er.
These data largely refer to exposures where ritonavir was used in combination therapy and not at therapeutic ritonavir doses but at lower doses as a pharmacokinetic enhancer for other PIs.
Disse begrænsede data indikerer ingen forøgelse i forekomsten af medfødte defekter sammenlignet med forekomsten fundet i populationsbaserede fødselsdefekt- overvågningssystemer.
These limited data indicate no increase in the rate of birth defects compared to rates observed in population-based birth defect surveillance systems.
Dyre data har vist reproduktionstoksicitet (se 5. 3).
Animal data have shown reproductive toxicity (see 5.3).
Anvendelse af Norvir kan overvejes under graviditet, hvis fordelene overstiger risikoen for fosteret.
The use of Norvir may be considered in pregnancy only when the benefits outweigh the risk to the foetus.
Ritonavir giver alvorlige interaktioner med orale kontraceptiva (OK- er).
Ritonavir adversely interacts with oral contraceptives (OCs).
20 Det vides ikke om dette lægemiddel udskilles i modermælken.
20 4.7 Effects on ability to drive and use machines
4. 7 Virkninger på evnen til at føre motorkøretøj eller betjene maskiner Der er ikke udført forsøg på effekten på evnen til at køre bil eller betjene maskiner.
No studies on the effects on the ability to drive and use machines have been performed.
Da somnolens og svimmelhed er kendte bivirkninger, bør dette tages i betragtning, når man kører bil eller anvender maskiner.
As somnolence and dizziness are known undesirable effects, this should be taken into account when driving or using machinery.
Norvir mikstur indeholderalkohol (43%).
Norvir oral solution contains alcohol (43%).
Bivirkninger i forbindelse med anvendelse af ritonavir som en farmakokinetisk forstærker afhænger af den konkrete samtidigt indgivne proteasehæmmer.
Adverse events associated with the use of ritonavir as a pharmacokinetic enhancer are dependent on the specific co-administered PI.
For oplysninger om bivirkninger henvises til produktresuméet for den samtidigt indgivne proteasehæmmer.
For information on adverse events refer to the SPC of the specific co-administered PI.
I de oprindelige kliniske forsøg (Fase II/ III) blev der rapporteret bivirkninger med mulig, sandsynlig eller ukendt relation til ritonavir hos ≥2% af 1033 patienter:
In the original clinical studies (Phase II/III), adverse events with possible, probable or unknown relationship to ritonavir were reported in ≥ 2% of 1033 patients.
Inden for hver frekvensgruppe er bivirkningerne opstillet efter faldende alvorlighed: meget almindelig > 1/ 10; almindelig > 1/ 100 til < 1/ 10; usædvanlig > 1/ 1. 000 til < 1/ 100; sjælden > 1/ 10. 000 til < 1/ 1. 000.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1000 to < 1/100); rare( > 1/10,000 to < 1/1,000).
Bivirkninger i kliniske forsøg og postmarketing hos voksne patienter Forstyrrelser i immunsystemet
Undesirable Effects in Clinical Studies and Post-marketing in Adult Patients Immune system disorders
Allergiske reaktioner, som omfatter urticaria, lettere hududslæt, bronkospasme og angioneurotisk ødem
Allergic reactions including urticaria, mild skin eruptions, bronchospasm and angioedema
Anafylaksi og Stevens- Johnsons syndrom
Anaphylaxis and Stevens Johnson syndrome
Nedsat antal leukocytter, nedsat hæmoglobin, nedsat antal neutrofile celler, forhøjet antal eosinofile celler
Decreased WBC, decreased haemoglobin, decreased neutrophils, increased eosinophils
Forhøjet antal leukocytter, forhøjet antal neutrofile celler, forlænget protrombintid
Increased WBC, increased neutrophils and increased prothrombin time
Ukendt hyppighed
Unknown frequency
Dehydrering, diabetes mellitus
Dehydration, diabetes mellitus
Hypertriglyceridæmi, hyperkolesterolæmi, hyperuricæmi
Hypertriglyceridaemia, hypercholesterolaemia, hyperuricaemia
Krampeanfald, synkope
Seizure, syncope
Kardilation
Vasodilation